Components:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 26.06.2023
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Camgesic: Each film-coated tablet contains Paracetamol (Camgesic) BP 450 mg, Orphenadrine citrate (Camgesic) BP 35 mg.
Camgesic Forte: Each film-coated tablet contains Paracetamol (Camgesic) BP 650 mg, Orphenadrine citrate (Camgesic) BP 35 mg.
Paracetamol (Camgesic) has analgesic and antipyretic properties and used for the short-term treatment of moderate pain, particularly after surgery, and for fever.
Orphenadrine is also used as to relieve pain due to skeletal muscle spasm and with the Paracetamol (Camgesic) used in the treatment of musculoskeletal and joint disorders.
Usual
Oral Dose:
Two tablets, three or four times daily.Or as prescribed by the physician.
History of hypersensitivity. Glaucoma; myasthenia gravis; prostatic hypertrophy; pyloric or duodenal obstruction. Severe renal & hepatic impairment.
The risk of Paracetamol (Camgesic) toxicity may be increased in patients receiving other potentially hepatotoxic drugs or drugs that induce liver microsomal enzymes. The absorption of Paracetamol (Camgesic) may be accelerated by drugs such as metoclopramide. Excretion may be affected and plasma concentrations altered when given with probenecid.
Colestyramine reduces the absorption of Paracetamol (Camgesic) if given within 1 hour of Paracetamol (Camgesic).
Orphenadrine is an inhibitor of the cytochrome P450 isoenzymes CYP2B6 which is involved in the metabolism of bupropion to its major metabolites, should be used with caution in patients also receiving bupropion.
Adverse effects of Paracetamol (Camgesic) are rare and usually mild, although haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Skin rashes and other hypersensitivity reactions occur occasionally.
Orphenadrine adverse effects include dryness of mouth with difficulty in swallowing and talking, thirst reduced bronchial secretions, dilation of the pupils with loss of accommodation and photophobia, flushing and dryness of skin, transient bradycardia followed by tachycardia with palpitation and arrhythmias, and difficulty in micturition as well as reduction in the tone and motility of the gastrointestinal tract leading to constipation.